Intellect Neurosciences Inc. (fka ILNS)

[itwillgetbetter]

Yeah I would like to put this issue to rest so as not to have to be forced to file complaints ect.

Yes they had to be talking if not there would have been issues addressed showing up on efile.This week hopefully ends this ligation.

One thing for certain or the way I understand regarding Ponezumab.It don't matter if they were testing ponezumab for the milestone payment to be acheived when the patent was issued.

They had a termination agreement section 7.5 60 days they did not terminate.section 3.1.3 states even if you terminate you still must pay for any patent milestone acheived before said termination.

This ongoing trial which is in factual dispute is clear evidence they continued work on Ponezumab.


THE U. S. PATENT MILESTONE PAYMENT UPON THE GRANT BY THE USPTO IN MAY 2012 OF A LICENSED PATENT TO INTELLECT WITH VALID CLAIMS THAT ENCOMPASS THE PFIZER COMPOUND PONEZUMAB FOR USE IN TREATING ALZHEIMER'S AND OTHER DISEASES

That to me says Ponezumab the compound method don't just have to be releated to Alzheimer's its states other diseases.You just don't know what the future holds and you want to cover every base.

Court:You guys are the owner of the product method and you want to make sure you are going to get compensated for everything and you going to write a contract that's going to cover all instances of maybe of pontential use not just actual use pontential infridgement.

Shapiro:Not infridgement section 1.10 license patent

Schedule one that claims that having claims that encompass ponezumab,broder but certainly by definition ponezumab.

Could go on and on but no need to.Point is that trial means nothing regarding weather or not payment was due for the patent milestone to be payable.

It is a factual dispute cause not only did they lie but continued to use Ponezumab A LICENSED PATENT TO INTELLECT WITH VALID CLAIMS THAT ENCOMPASS THE PFIZER COMPOUND PONEZUMAB FOR USE IN TREATING ALZHEIMER'S AND OTHER DISEASES

(OTHER DISEASES) meaning this ongoing trial.

http://www.clinicaltrial.gov/ct2/show/NCT01821118?term=ponezumab&rank=5